Topoisomerase I poisoning results in PARP-mediated replication fork reversal. - Wikidata - wikimedia - TriplyDB

Topoisomerase I poisoning results in PARP-mediated replication fork reversal.

Topoisomerase I poisoning results in PARP-mediated replication fork reversal.

http://www.wikidata.org/entity/Q39386006

about

Human GEN1 and the SLX4-associated nucleases MUS81 and SLX1 are essential for the resolution of replication-induced Holliday junctions Polyubiquitinated PCNA recruits the ZRANB3 translocase to maintain genomic integrity after replication stress Targeting DNA Replication Stress for Cancer Therapy Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy Repair of oxidative DNA damage and cancer: recent progress in DNA base excision repair Pleiotropic cellular functions of PARP1 in longevity and aging: genome maintenance meets inflammation Rescuing stalled or damaged replication forks Synthetic lethality and cancer: cohesin and PARP at the replication fork Interaction with PALB2 Is Essential for Maintenance of Genomic Integrity by BRCA2 Replication stress: getting back on track Recovery from the DNA Replication Checkpoint The Causes and Consequences of Topological Stress during DNA Replication Preventing replication fork collapse to maintain genome integrity Replication stress in Mammalian cells and its consequences for mitosis NUCKS1 is a novel RAD51AP1 paralog important for homologous recombination and genome stability Genome-destabilizing effects associated with top1 loss or accumulation of top1 cleavage complexes in yeast Human HLTF mediates postreplication repair by its HIRAN domain-dependent replication fork remodelling.Single-Molecule Supercoil Relaxation Assay as a Screening Tool to Determine the Mechanism and Efficacy of Human Topoisomerase IB Inhibitors.TOPOISOMERASE1α Acts through Two Distinct Mechanisms to Regulate Stele and Columella Stem Cell Maintenance.Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers.Mechanisms controlling the smooth muscle cell death in progeria via down-regulation of poly(ADP-ribose) polymerase 1.New frontiers in the treatment of colorectal cancer: Autophagy and the unfolded protein response as promising targets Synthetic cytotoxicity: digenic interactions with TEL1/ATM mutations reveal sensitivity to low doses of camptothecin PARG is dispensable for recovery from transient replicative stress but required to prevent detrimental accumulation of poly(ADP-ribose) upon prolonged replicative stress.Tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2).The N-terminus of Mcm10 is important for interaction with the 9-1-1 clamp and in resistance to DNA damage.Identification of novel PARP inhibitors using a cell-based TDP1 inhibitory assay in a quantitative high-throughput screening platform.Poisoning of mitochondrial topoisomerase I by lamellarin D Cellular deficiency of Werner syndrome protein or RECQ1 promotes genotoxic potential of hydroquinone and benzo[a]pyrene exposure.Causes and consequences of replication stress.Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies.DNA structure-specific priming of ATR activation by DNA-PKcs Noncovalent interactions with SUMO and ubiquitin orchestrate distinct functions of the SLX4 complex in genome maintenance.Slx8 removes Pli1-dependent protein-SUMO conjugates including SUMOylated topoisomerase I to promote genome stability.Deregulated origin licensing leads to chromosomal breaks by rereplication of a gapped DNA template.Poly(ADP-ribosyl) glycohydrolase prevents the accumulation of unusual replication structures during unperturbed S phase Mec1/ATR regulates the generation of single-stranded DNA that attenuates Tel1/ATM signaling at DNA ends.Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells.DNA2 drives processing and restart of reversed replication forks in human cells.

P2860

Q24337537-EEBD966A-58FB-405D-B576-5FC21AA08F84 Q24338351-AB7E10B7-E403-488A-AA42-9CF6547BAD91 Q26739923-19BB9D83-166F-44E0-B03D-F2310BE6BB97 Q26796576-D0AFF016-B266-40EE-AEAC-0A2AC62D00B9 Q26822957-4866E58E-6449-4FC7-A87F-C6378BEEB53F Q26858894-4ABD7704-28DF-448C-97FB-B3B1581A4842 Q26859667-AD3A8185-38A4-487D-BC61-29FF78E7F203 Q26991603-58A8D07C-F52A-458C-BADB-57245CCD709E Q27308072-B2CA18DA-A4C1-4FC0-9B5C-9AA78DBBF322 Q28067138-75B93A97-552C-4156-8EA3-97C3E913E374 Q28073260-1B890F65-58BC-4BF7-B8C7-8AB683C03C81 Q28077125-C2348984-027D-4E42-A7B7-C65DD2A7CA2E Q28083804-1B6589D1-155B-4590-A2E9-5DE23AD59988 Q28087011-3BC38AE7-3785-482D-B796-B73B8FCD45CB Q28115978-007E2457-EEE8-4DCA-9F60-F7C01D1ECC0C Q28545243-0D7B6AA4-C1F6-4E71-B33D-DCD06CB1CB32 Q29871515-5E43FE05-8DE4-4809-BBB3-67062E912CB2 Q30673594-58E7F7F4-55C3-400F-8726-5C840AA8E953 Q33362758-755239FD-F05D-4B0D-AE04-A56DF9480C91 Q33603605-922296E8-CF74-488A-B719-842F74E50395 Q33688658-80EEA2C2-4138-4DBD-BCAF-3AAC541BC221 Q33730599-2A5BC7C6-6D6E-4643-8377-3860660A5AC0 Q33731804-BDBCCC69-18BF-4360-B6FB-07B174F102AE Q33779587-71AB285A-B2E8-4A53-9664-ED890C5FBBB9 Q33843183-713CD9B9-85C6-4947-9EF5-E40DC030AA3F Q33875792-177B0464-6EC8-46C6-B9E6-C1CAD5C573E6 Q33983483-373584D7-8B9C-4C37-9F80-1BBD1F8E3D4F Q34017010-4F67C6B7-325D-4F03-9418-E64A801318F1 Q34024641-E3FADB86-C498-4DC4-A493-541767CC30D3 Q34324695-B83F6A25-1809-4E7F-8856-39927EC8693D Q34394094-EBB3208E-B7A1-4A51-BF98-72B2305245CB Q34536666-BA063045-3301-4704-8F57-7E1208CD05A1 Q34880194-E84FA9DE-14AA-408E-9DB4-0DE6F5090F8B Q34898909-909D2F67-F2FC-435C-AB90-F7FC42899BA9 Q34927156-B9347142-C9D1-4FAE-8327-29397648D705 Q35057886-0EC326FD-9D18-4DFA-99D2-9B8F77DF9B28 Q35069579-14AD8D69-45B2-402F-886B-2E1A78F809F5 Q35072400-C348B5E1-864A-46EE-97AE-9F66EBAF96D7 Q35141185-C4BC51C7-7D67-45F6-8FF9-230749462565 Q35141202-0330E256-61CC-41EB-8256-BC0EFF3A44B0

P2860

Topoisomerase I poisoning results in PARP-mediated replication fork reversal.

http://www.wikidata.org/entity/Q39386006

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Topoisomerase I poisoning results in PARP-mediated replication fork reversal.

@en

Topoisomerase I poisoning results in PARP-mediated replication fork reversal.

@nl

type

label

Topoisomerase I poisoning results in PARP-mediated replication fork reversal.

@en

Topoisomerase I poisoning results in PARP-mediated replication fork reversal.

@nl

prefLabel

Topoisomerase I poisoning results in PARP-mediated replication fork reversal.

@en

Topoisomerase I poisoning results in PARP-mediated replication fork reversal.

@nl

P1433

Q39386006-E1DD95A1-F6AC-4785-98BD-7E08217A3294

P1476

Q39386006-E07740D1-9817-4ED9-BD33-0D773C175752

P2093

Q39386006-1B3DCCB9-69EC-4B81-ACA7-43EEEE482447

Q39386006-744EE24A-ACE8-422A-9BA6-2600ACBD05FD

Q39386006-87BC29C8-6CE2-4D14-AC50-E6338E4B2C99

Q39386006-C0B9F966-08C7-424A-BA32-86AFAB085054

P2860

Q39386006-072098CB-9771-432F-8047-13395E513AFD

Q39386006-0B9D04A0-0E77-454C-A70B-B3FDCAE2FA99

Q39386006-0BA9B06B-3D1F-4A0F-9F1B-760B5908CA89

Q39386006-19DD282F-BC22-45B3-8B2F-B5BD1C4DFEB5

Q39386006-1B4E10A6-E01F-4CE8-B78D-9D367CA6493E

Q39386006-26EEF9DA-6FEA-479F-BF31-C37B65E8BE01

Q39386006-2D7BF7A1-7090-4C4E-A1F9-C4396864A89C

Q39386006-3B722BC9-8BA9-4244-8CE7-788BA6D98C89

Q39386006-400D3F8D-9A7C-4044-AFD8-142E8DAF8E3A

Q39386006-5208E9D7-3664-4491-B5E4-CA10CD9D1ED7

P2888

Q39386006-EE14A5E1-8264-432F-85A0-0AED89CDEA1D

P304

Q39386006-E821AA97-4279-439D-942D-1F12F7B4B668

P31

Q39386006-1526A7AC-A48A-49DA-9F12-9C36C0368B3D

P356

Q39386006-E3EC0827-8F72-4A76-8DA7-F5575CA1E0EE

P433

Q39386006-B086E285-C776-40BF-ACCC-8057A011DD08

P478

Q39386006-ABB7C4D3-91BF-483D-87FA-BA8DA8BE1171

P50

Q39386006-11ABD628-E54B-4FC7-ADC7-B0E5169F9B75

Q39386006-19EA90C1-57E8-4E19-BAF1-AAD9A91EE694

Q39386006-19F6182F-EC3B-4A75-9E70-7F9140C1BAD6

Q39386006-AAAD9E84-C32D-4D5C-BDF1-2354CBF723BC

Q39386006-D1B36D59-33F4-419E-80CE-80F7FFCDE1D5

P577

Q39386006-CA402365-F7FD-4462-B8AE-2C0D5D707C4D

P5875

Q39386006-6F38D3BA-A756-472E-885E-239D68CE6B59

P698

Q39386006-39D59609-147B-4322-B650-E2D4E0E7E20A

P921

Q39386006-3cd74dd0-2827-48d8-b495-d59b3fd0641f

P356

P1433

Nature Structural & Molecular Biology

P1476

Topoisomerase I poisoning results in PARP-mediated replication fork reversal.

@en

P2093

Andrea Cocito

http://www.w3.org/2001/XMLSchema#string

Arnab Ray Chaudhuri

http://www.w3.org/2001/XMLSchema#string

Raquel Herrador

http://www.w3.org/2001/XMLSchema#string

Yoshitami Hashimoto

http://www.w3.org/2001/XMLSchema#string

P2860

A genome-wide camptothecin sensitivity screen identifies a mammalian MMS22L-NFKBIL2 complex required for genomic stability

Human CtIP promotes DNA end resection

Replication termination at eukaryotic chromosomes is mediated by Top2 and occurs at genomic loci containing pausing elements

S-phase checkpoint proteins Tof1 and Mrc1 form a stable replication-pausing complex.

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Fork reversal and ssDNA accumulation at stalled replication forks owing to checkpoint defects

Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease

Next generation topoisomerase I inhibitors: Rationale and biomarker strategies

Topoisomerase I inhibitors: camptothecins and beyond

PARP inhibition: PARP1 and beyond

P2888

P304

417-423

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NSMB.2258

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Rodrigo Bermejo

Daniele Fachinetti

Vincenzo Costanzo

P577

2012-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221886544

http://www.w3.org/2001/XMLSchema#string

P698

22388737

http://www.w3.org/2001/XMLSchema#string

P921